AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) had its price target upped by Maxim Group from $2.00 to $4.00 in a research report report published on Wednesday. Maxim Group currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on AEZS. Zacks Investment Research upgraded AEterna Zentaris from a sell rating to a hold rating in a research report on Tuesday, July 11th. HC Wainwright set a $3.00 price objective on AEterna Zentaris and gave the stock a buy rating in a research report on Wednesday, July 5th.

AEterna Zentaris (NASDAQ:AEZS) traded up 26.50% during midday trading on Wednesday, reaching $2.96. 42,718,328 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $1.05 and its 200 day moving average is $2.16. The firm’s market capitalization is $42.43 million. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $5.59.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.85 million. During the same quarter in the prior year, the firm posted ($0.37) EPS. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities analysts anticipate that AEterna Zentaris will post ($1.39) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AEterna Zentaris Inc. (AEZS) Price Target Increased to $4.00 by Analysts at Maxim Group” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.